Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia

Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia

Autor Abilio, V. C. Google Scholar
Silva, R. H. Google Scholar
Carvalho, R. C. Google Scholar
Grassl, C. Google Scholar
Calzavara, M. B. Google Scholar
Registro, S. Google Scholar
D'Almeida, V Google Scholar
Ribeiro, R. D. Google Scholar
Frussa-Filho, R. Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo Tardive dyskinesia, the most serious iatrogenic movement disorder, has been tentatively associated with nigrostriatal dopaminergic supersensitivity and with oxidative stress. It is also suggested that long-term neuroleptic treatment does not cause oral dyskinesia (OD), but interacts with some substrate of brain aging, resulting in the premature emergence of OD, that can occur spontaneously with aging. in order to investigate a possible role of nigrostriatal dopaminergic supersensitivity and of oxidative stress in aging- and reserpine-induced OD, the stereotyped behavior induced by dopaminergic agonists, a functional index of dopaminergic striatal activity, as well as the striatal antioxidant enzymes glutathione peroxidase and catalase were assessed. We demonstrate that, opposite to normotensive Wistar rats (NWR), spontaneously hypertensive rats (SHR) do not develop aging- or reserpine-OD. There were no differences between NWR and SHR in stereotyped behavior or in striatal glutathione peroxidase activity. Adult and old SHR presented higher striatal catalase activity relative to NWR, and aging increased it only in SHR. the catalase inhibitor aminotriazole reverted the absence of aging- and reserpine-induced OD in SHR. Our results suggest an important role of striatal catalase in the development of reserpine- and aging-induced OD. (C) 2004 Elsevier B.V. All rights reserved.
Palavra-chave oral dyskinesia
catalase
aging
reserpine
oxidative stress
nigrostriatal dopaminergic system
Idioma Inglês
Data de publicação 2004-08-01
Publicado em Neuropharmacology. Oxford: Pergamon-Elsevier B.V., v. 47, n. 2, p. 263-272, 2004.
ISSN 0028-3908 (Sherpa/Romeo, fator de impacto)
Publicador Elsevier B.V.
Extensão 263-272
Fonte http://dx.doi.org/10.1016/j.neuropharm.2004.04.003
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000222841100012
Endereço permanente http://repositorio.unifesp.br/handle/11600/27858

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta